MCF Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

MCF Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8K	Buy	+100	New	+$13.5K	﹤0.01%	951
2026 Q1	–	Sell	-375	Closed	-$45.7K	–	1407
2025 Q4	$45.7K	Buy	+375	New	+$43K	﹤0.01%	531
2018 Q2	–	Sell	-43	Closed	-$4K	–	500
2018 Q1	$4K	Hold	43	–	–	﹤0.01%	391
2017 Q4	$4K	Hold	43	–	–	﹤0.01%	394
2017 Q3	$4K	Hold	43	–	–	﹤0.01%	412
2017 Q2	$3K	Buy	+43	New	+$3.05K	﹤0.01%	429

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

MCF Advisors's XBI Position: Q2 2026 in Review

MCF Advisors opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 100 shares worth $15.8K. The stake represents ﹤0.01% of the portfolio and ranks #951 among its holdings. This is a return to the name: MCF Advisors previously reported a position in XBI as recently as Q4 2025.

MCF Advisors first reported a position in XBI in Q2 2017 and has held it in 6 quarters since. The position peaked at $45.7K in Q4 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

MCF Advisors held 100 shares of State Street SPDR S&P Biotech ETF worth $15.8K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new MCF Advisors position in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #951 holding.
MCF Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 6 quarters since.
MCF Advisors's State Street SPDR S&P Biotech ETF position peaked at $45.7K in Q4 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.